Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

A study of more than 100,000 patients has revealed that, for patients with blockages in multiple arteries, those who opt for coronary artery bypass grafting (CABG) are less likely to die from their condition, less likely to need additional surgery, and less likely to have a heart attack than patients who choose to undergo a stent procedure.

News | Stents

Patients with Multiple Artery Blockages Undergoing Coronary Artery Bypass Surgery Fare Better, Live Longer than Those Who Opt for Stenting

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

January 23, 2023

Newest Addition to Company’s Zoom Stroke Solution Provides an Additional Option for Achieving Intracranial Access to Treat Patients for Ischemic Stroke

News | Stroke

Imperative Care Announces FDA Clearance and Initial Cases of Zoom RDL

January 23, 2023 — Imperative Care, Inc., announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom ...

January 23, 2023

$Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market$

News | Cardiovascular Business

Shockwave Medical Announces Agreement to Acquire Neovasc

January 19, 2023 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat ...

January 19, 2023

Sponsored Content

Blog | Contrast Media Injectors

BLOG: Enhancing Efficiency and Patient Care with a Modern Injector

Adjustable parameters on the ACIST® CVI® Contrast Delivery System include, flow rate, volume, pressure limit, rise time ...

August 22, 2023

$Neovasc’s Innovative Reducer System will target the estimated $5 billion refractory angina market$

News | Structural Heart

Abbott Receives FDA Approval for Navitor TAVI System

January 19, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest ...

January 19, 2023

Behavioral science is being applied in unique ways for enterprise-imaging product design. #webinar

Sponsored Content | Webinar | Enterprise Imaging

WEBINAR: How to Transform Imaging with Behavioral Science — Now Available On Demand

Behavioral science is being applied in unique ways for enterprise-imaging product design.

Behavioral science is the ...

January 19, 2023

SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

News | Drug-Eluting Balloons

MedAlliance Selution SLR is the First DEB to Receive Coronary de novo IDE Approval, its Fourth FDA IDE DEB Approval

January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA ...

January 12, 2023

Sponsored Content

As medical advancements continue to push the boundaries of what is possible in the field of structural heart interventions, the importance of enterprise imaging has become increasingly evident.

Blog | Enterprise Imaging

BLOG: The Power of Enterprise Imaging in Structural Heart Procedures

As medical advancements continue to push the boundaries of what is possible in the field of structural heart ...

August 10, 2023

ADVANCE Trial compares sac regression in the Medtronic Endurant II/IIs stent graft system and the Gore® Excluder AAA Device Family systems

News | Stent Grafts

Medtronic Announces First Enrollment in Head-to-head Global Randomized Trial Evaluating Durability of Endovascular Aneurysm Repair

January 12, 2023 — Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized ...

January 12, 2023

Alameda, CA-based global healthcare company Penumbra has announced Food & Drug Administration (FDA) clearance and launch of Lightning Flash, which the company reports is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus.

News | Cardiovascular Business

FDA Clearance and Launch Granted to Penumbra Mechanical Thrombectomy System

January 11, 2023 — The Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug ...

January 11, 2023

News | Embolic Protection Devices

Shockwave Intravascular Lithotripsy-assisted TMVR Shows Promise for Patients with Severe Stenosis and Regurgitation

January 11, 2023 — In recent years, transcatheter mitral valve replacement (TMVR) treatment and technology has evolved ...

January 11, 2023

Sponsored Content

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the wealth of technological advancements, bringing the necessary tools together in a streamlined workflow has remained a challenge for clinicians

Case Study | Baylor Scott and White Heart Hospital

Contemporary PCI: Utilizing State-of-the-Art Technology to Achieve the Best Outcomes

While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...

May 05, 2023

News | Cardiovascular Business

ReCor Medical Names Lara Barghout President and Chief Executive Officer

January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...

January 09, 2023

$TGCV is an emerging cardiovascular disorder characterized by diffuse narrowing coronary atherosclerosis with triglyceride (TG) deposition caused by defective intracellular lipolysis. TGCV is an often-undiagnosed condition in patients who are resistant to standard therapies. Panels A and B concern two patients in their 60s with refractory angina pectoris and diabetes mellitus. After being diagnosed with TGCV, they started dietary intake of tricaprin. Their symptoms improved within a couple of months. Follow-$